Abughanimeh O et al., 2020-02-25: Case report of an 83-year-old man with stage IVA diffuse large B-cell lymphoma who declined chemotherapy and took fenbendazole about 1 g/day, with serial CT and PET/CT showing improving lymphadenopathy over months; the authors say causation is unknown.
He started to take fenbendazole 1g daily based on self-research (used to take between 1-6 tabs daily based on his symptoms).
Case Presentation (unpaginated HTML)
Abughanimeh O et al., 2020-02-25: Case report of an 83-year-old man with stage IVA diffuse large B-cell lymphoma who declined chemotherapy and took fenbendazole about 1 g/day, with serial CT and PET/CT showing improving lymphadenopathy over months; the authors say causation is unknown. Study type: single case report, n=1, USA (University of Nebraska Medical Center). Dose/schedule as published: 1 g daily, self-titrated between 1 and 6 tablets daily, reduced to 1-3 tablets then 3 pills weekly after 6-9 months because of peripheral neuropathy; route oral; no duration cap stated. Other treatment: none – the patient declined chemotherapy. Outcome measured by CT and PET/CT and by clinical course, not by biopsy. Comparator: none. Funding and conflicts: the article carries no funding or disclosure statement. Published 2020-02-25 (received 2019-12-24). Not indexed in PubMed; the publisher hosts the full text. Authors' own caveat: 'Whether it's realted to Fenbendazole or other factors still unknown.' Also filed as FBE-40 (claims C2, C4). Study type: case report.
